WO2004022577A3 - Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin - Google Patents

Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin Download PDF

Info

Publication number
WO2004022577A3
WO2004022577A3 PCT/US2003/028073 US0328073W WO2004022577A3 WO 2004022577 A3 WO2004022577 A3 WO 2004022577A3 US 0328073 W US0328073 W US 0328073W WO 2004022577 A3 WO2004022577 A3 WO 2004022577A3
Authority
WO
WIPO (PCT)
Prior art keywords
long acting
tissue protective
erythropoietins
protective activity
chemically modified
Prior art date
Application number
PCT/US2003/028073
Other languages
French (fr)
Other versions
WO2004022577A2 (en
Inventor
Anthony Cerami
John Smart
Michael Brines
Carla Cerami
Original Assignee
Warren Pharmaceuticals Inc
Anthony Cerami
John Smart
Michael Brines
Carla Cerami
Kenneth S Warren Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warren Pharmaceuticals Inc, Anthony Cerami, John Smart, Michael Brines, Carla Cerami, Kenneth S Warren Inst Inc filed Critical Warren Pharmaceuticals Inc
Priority to EA200500473A priority Critical patent/EA007812B1/en
Priority to BR0314152-7A priority patent/BR0314152A/en
Priority to AU2003273297A priority patent/AU2003273297A1/en
Priority to CA002497960A priority patent/CA2497960A1/en
Priority to MXPA05002617A priority patent/MXPA05002617A/en
Priority to EP03755796A priority patent/EP1545586A4/en
Priority to JP2004534745A priority patent/JP2006511468A/en
Priority to BRPI0409650-9A priority patent/BRPI0409650A/en
Priority to CNA2004800329545A priority patent/CN1882355A/en
Priority to PCT/US2004/007133 priority patent/WO2005025606A1/en
Publication of WO2004022577A2 publication Critical patent/WO2004022577A2/en
Publication of WO2004022577A3 publication Critical patent/WO2004022577A3/en
Priority to IS7731A priority patent/IS7731A/en
Priority to US11/075,957 priority patent/US20050176627A1/en
Priority to NO20051714A priority patent/NO20051714L/en
Priority to IL174178A priority patent/IL174178A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)

Abstract

Methods for increasing the hematocrit of an individual while maintaining the tissue protective activities of endogenous through the administration of a pharmaceutical compound containing chemically modified long acting erythropoietin. Also disclosed are the new chemically modified long acting erythropoietins, methods of producing the chemically modified long acting erythropoietins, and compositions comprising the chemically modified long acting erythropoietins.
PCT/US2003/028073 2002-09-09 2003-09-09 Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin WO2004022577A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
EA200500473A EA007812B1 (en) 2002-09-09 2003-09-09 Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
BR0314152-7A BR0314152A (en) 2002-09-09 2003-09-09 Methods for regulating hematocrit level in humans, for preparing an erythropoietin product, and for treating anemia in patients at risk of tissue injury, man-made erythropoietin product, and pharmaceutical composition
AU2003273297A AU2003273297A1 (en) 2002-09-09 2003-09-09 Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
CA002497960A CA2497960A1 (en) 2002-09-09 2003-09-09 Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
MXPA05002617A MXPA05002617A (en) 2002-09-09 2003-09-09 Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin.
EP03755796A EP1545586A4 (en) 2002-09-09 2003-09-09 Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
JP2004534745A JP2006511468A (en) 2002-09-09 2003-09-09 Long-acting erythropoietin maintains the tissue protective activity of endogenous erythropoietin
BRPI0409650-9A BRPI0409650A (en) 2003-09-09 2004-03-08 methods for regulating hematocrit and human levels, artificial erythropoietin products, methods for preparing an erythropoietin product and for treating anemia in patients at risk of tissue damage, and, pharmaceutical composition
CNA2004800329545A CN1882355A (en) 2003-09-09 2004-03-08 Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
PCT/US2004/007133 WO2005025606A1 (en) 2003-09-09 2004-03-08 Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
IS7731A IS7731A (en) 2002-09-09 2005-03-08 Long-acting erythropoietin that maintain the tissue-protective activity of endogenous erythropoietin
US11/075,957 US20050176627A1 (en) 2002-09-09 2005-03-09 Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
NO20051714A NO20051714L (en) 2002-09-09 2005-04-06 Long-acting Erythropoietins That Maintain Tissue Protective Activity to Endogenous Erythropoietin
IL174178A IL174178A0 (en) 2002-09-09 2006-03-08 Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40902002P 2002-09-09 2002-09-09
US60/409,020 2002-09-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/075,957 Continuation-In-Part US20050176627A1 (en) 2002-09-09 2005-03-09 Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin

Publications (2)

Publication Number Publication Date
WO2004022577A2 WO2004022577A2 (en) 2004-03-18
WO2004022577A3 true WO2004022577A3 (en) 2004-09-16

Family

ID=31978712

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/028073 WO2004022577A2 (en) 2002-09-09 2003-09-09 Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin

Country Status (15)

Country Link
EP (1) EP1545586A4 (en)
JP (1) JP2006511468A (en)
KR (1) KR20050083682A (en)
CN (2) CN101371920A (en)
AU (1) AU2003273297A1 (en)
BR (1) BR0314152A (en)
CA (1) CA2497960A1 (en)
EA (1) EA007812B1 (en)
IL (1) IL174178A0 (en)
IS (1) IS7731A (en)
MX (1) MXPA05002617A (en)
NO (1) NO20051714L (en)
PL (1) PL375741A1 (en)
WO (1) WO2004022577A2 (en)
ZA (1) ZA200505423B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
WO2006061853A2 (en) * 2004-12-10 2006-06-15 Serum Institute Of India Limited Novel erythropoietic compounds and a process for producing erythropoietic compounds
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
CA3079319A1 (en) 2005-08-05 2007-02-15 Araim Pharmaceuticals, Inc. Tissue protective peptides and uses thereof
SG10202011946PA (en) 2008-01-22 2020-12-30 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CN101671388B (en) * 2008-09-09 2013-01-02 曹国栋 Blood brain barrier penetrable erythropoietin (EPO) and application thereof
RU2475273C1 (en) * 2012-04-02 2013-02-20 Юлия Николаевна Козлова Method of obtaining polymeric cement of medical purpose
CN102746405B (en) * 2012-07-24 2013-08-21 深圳赛保尔生物药业有限公司 Continuous pegylation reaction method for recombinant human erythropoietin (EPO)
RU2664588C2 (en) * 2015-11-05 2018-08-21 Закрытое Акционерное Общество "Биокад" Extended factor of human erythropoiesis and a therapeutic agent based thereon
EP3448415A4 (en) 2016-04-29 2019-11-06 Araim Pharmaceuticals, Inc. Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage
CN112741895A (en) * 2021-01-19 2021-05-04 中国人民解放军陆军军医大学 Application of EPO analog in preparing medicament for treating sepsis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340742B1 (en) * 1999-07-02 2002-01-22 Roche Diagnostics Gmbh Erythropoietin conjugates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081405A2 (en) * 2000-04-21 2001-11-01 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
DK1311285T4 (en) * 2000-05-15 2017-07-24 Hoffmann La Roche Liquid pharmaceutical composition containing an erythropoietin derivative

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340742B1 (en) * 1999-07-02 2002-01-22 Roche Diagnostics Gmbh Erythropoietin conjugates

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EGRIE ET AL: "Development and Characterization of novel erythropoiesis stimulating protein (NESP)", NEPHROL. DIAL. TRANSPLANT, vol. 16, no. SUPPLEMENT 3, 2001, pages 3 - 13, XP001059695 *
HANSEN ET AL: "A randomized, blinded, placebo-controlled, phase II, dose finding study of ARANESP in patients with lymphoproliferative malignancies", BLOOD, vol. 96, no. 11, November 2000 (2000-11-01), pages 155B, XP002978246 *
VANSTEENKISTE ET AL: "Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia", EXPERT. OPIN. BIOL. THER., vol. 3, no. 3, 2003, pages 501 - 508, XP002978255 *

Also Published As

Publication number Publication date
CN1729015A (en) 2006-02-01
IS7731A (en) 2005-03-08
AU2003273297A8 (en) 2004-03-29
IL174178A0 (en) 2006-08-01
NO20051714L (en) 2005-06-06
EP1545586A4 (en) 2007-09-26
BR0314152A (en) 2005-07-12
AU2003273297A1 (en) 2004-03-29
KR20050083682A (en) 2005-08-26
CA2497960A1 (en) 2004-03-18
EA007812B1 (en) 2007-02-27
ZA200505423B (en) 2008-08-27
EP1545586A2 (en) 2005-06-29
EA200500473A1 (en) 2005-10-27
PL375741A1 (en) 2005-12-12
JP2006511468A (en) 2006-04-06
CN101371920A (en) 2009-02-25
MXPA05002617A (en) 2005-09-08
WO2004022577A2 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
EP2527342A3 (en) Derivatives of UK-2A
EP1072254A4 (en) Food compositions, compositions for oral cavity and medicinal compositions for preventing or treating periodontosis and method for preventing or treating periodontosis
CA2286409A1 (en) Cosmetic and/or dermatological compound containing at least one extract of blackberry, at least one extract of skullcap and at least one salicylic acid derivative
IL163831A0 (en) Derivatives of aminoindazoles, method of preparation and intermediates of the method as drugs pharmaceutical compounds containing
WO2004014322A3 (en) Immunomodulatory compositions, methods of making, and methods of use thereof
WO2003059276A3 (en) Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
NO20051714L (en) Long-acting Erythropoietins That Maintain Tissue Protective Activity to Endogenous Erythropoietin
WO2004017918A3 (en) Method of preparing dry powder inhalation compositions
AU2003216934A1 (en) Benzoxazinone derivatives, the preparation and use thereof as medicaments
CA2309796A1 (en) Carbonate derivatives of retinol, process for their preparation and uses
WO2004093800A3 (en) Thyronamine derivatives and analogs and methods of use thereof
AU2003239389A1 (en) Opioid receptor antagonists
WO2003028475A1 (en) Feeds and fertilizers containing pentacyclic triterpenes
WO2003072030A3 (en) Methods for preventing or treating cardiac arrhythmia
WO2001027110A3 (en) Bicyclic imidazo-3-yl-amine derivatives which are substituted on the sixth ring
DK0888327T3 (en) Benzopyran derivatives which have antagonistic action against leukotrienes
AU2003301857A1 (en) New process for the preparation of racemic ((2s(2r*(r(r*)))) and ((2r(2s*(s(s*))))-(plus or minus)- alpha,alpha' -(imino-bis(methylene))bis(6-fluoro-chroman-2-methanol) and its pure (2s(2r*(r(r*)and
EP1498104A4 (en) Hair growth tonic
EP1602645A4 (en) Nitrogenous heterocyclic derivative having 2,6-disubstituted styryl
AU2003236118A1 (en) An antispastic, analgetic pharmaceutical composition and the preparation method thereof as well as the quality control technique therefor
AU2002349506A1 (en) Novel enantiomers of tetrahydroisoquinoline derivatives and their pharmaceutically acceptable salts, their preparations and pharmaceutical compositions
HUP0600084A2 (en) Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient
AU2003246566A1 (en) Administration form for the oral administration of active substances, vitamins, and/or nutrients
EP1550667A4 (en) Tyrosinase activity controlling agents, process for producing the same and external preparations containing the same
WO2005005382A3 (en) Compounds, compositions and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2497960

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004534745

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020057004045

Country of ref document: KR

Ref document number: PA/a/2005/002617

Country of ref document: MX

Ref document number: 167339

Country of ref document: IL

Ref document number: 375741

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 539009

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 557/CHENP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003755796

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200500473

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 20038249154

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003755796

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200505423

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1-2005-500476

Country of ref document: PH

WWP Wipo information: published in national office

Ref document number: 1020057004045

Country of ref document: KR